362 related articles for article (PubMed ID: 18241079)
1. The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile.
Ferracin M; Gafà R; Miotto E; Veronese A; Pultrone C; Sabbioni S; Lanza G; Negrini M
J Pathol; 2008 Apr; 214(5):594-602. PubMed ID: 18241079
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
Hum Pathol; 2007 Jun; 38(6):842-9. PubMed ID: 17350669
[TBL] [Abstract][Full Text] [Related]
3. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
Goel A; Nagasaka T; Arnold CN; Inoue T; Hamilton C; Niedzwiecki D; Compton C; Mayer RJ; Goldberg R; Bertagnolli MM; Boland CR
Gastroenterology; 2007 Jan; 132(1):127-38. PubMed ID: 17087942
[TBL] [Abstract][Full Text] [Related]
4. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.
Dahlin AM; Palmqvist R; Henriksson ML; Jacobsson M; Eklöf V; Rutegård J; Oberg A; Van Guelpen BR
Clin Cancer Res; 2010 Mar; 16(6):1845-55. PubMed ID: 20197478
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
[TBL] [Abstract][Full Text] [Related]
6. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.
Ogino S; Cantor M; Kawasaki T; Brahmandam M; Kirkner GJ; Weisenberger DJ; Campan M; Laird PW; Loda M; Fuchs CS
Gut; 2006 Jul; 55(7):1000-6. PubMed ID: 16407376
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
8. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.
Lee S; Cho NY; Yoo EJ; Kim JH; Kang GH
Arch Pathol Lab Med; 2008 Oct; 132(10):1657-65. PubMed ID: 18834226
[TBL] [Abstract][Full Text] [Related]
9. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
[TBL] [Abstract][Full Text] [Related]
10. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.
Karpinski P; Ramsey D; Grzebieniak Z; Sasiadek MM; Blin N
Mol Cancer Res; 2008 Apr; 6(4):585-91. PubMed ID: 18403637
[TBL] [Abstract][Full Text] [Related]
11. BRAF mutation is associated with the CpG island methylator phenotype in colorectal cancer from young patients.
Ang PW; Li WQ; Soong R; Iacopetta B
Cancer Lett; 2009 Jan; 273(2):221-4. PubMed ID: 18778891
[TBL] [Abstract][Full Text] [Related]
12. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer.
Sanchez JA; Krumroy L; Plummer S; Aung P; Merkulova A; Skacel M; DeJulius KL; Manilich E; Church JM; Casey G; Kalady MF
Br J Surg; 2009 Oct; 96(10):1196-204. PubMed ID: 19787768
[TBL] [Abstract][Full Text] [Related]
13. Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype.
English DR; Young JP; Simpson JA; Jenkins MA; Southey MC; Walsh MD; Buchanan DD; Barker MA; Haydon AM; Royce SG; Roberts A; Parry S; Hopper JL; Jass JJ; Giles GG
Cancer Epidemiol Biomarkers Prev; 2008 Jul; 17(7):1774-80. PubMed ID: 18628431
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
Ogino S; Kawasaki T; Kirkner GJ; Ogawa A; Dorfman I; Loda M; Fuchs CS
J Pathol; 2006 Oct; 210(2):147-54. PubMed ID: 16850502
[TBL] [Abstract][Full Text] [Related]
15. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer.
Ogino S; Kawasaki T; Kirkner GJ; Suemoto Y; Meyerhardt JA; Fuchs CS
Gut; 2007 Nov; 56(11):1564-71. PubMed ID: 17339237
[TBL] [Abstract][Full Text] [Related]
16. p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers.
Bond CE; Umapathy A; Ramsnes I; Greco SA; Zhen Zhao Z; Mallitt KA; Buttenshaw RL; Montgomery GW; Leggett BA; Whitehall VL
Int J Cancer; 2012 Apr; 130(7):1567-76. PubMed ID: 21557216
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.
Nosho K; Irahara N; Shima K; Kure S; Kirkner GJ; Schernhammer ES; Hazra A; Hunter DJ; Quackenbush J; Spiegelman D; Giovannucci EL; Fuchs CS; Ogino S
PLoS One; 2008; 3(11):e3698. PubMed ID: 19002263
[TBL] [Abstract][Full Text] [Related]
18. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.
Ogino S; Nosho K; Kirkner GJ; Kawasaki T; Meyerhardt JA; Loda M; Giovannucci EL; Fuchs CS
Gut; 2009 Jan; 58(1):90-6. PubMed ID: 18832519
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability.
Kakar S; Deng G; Sahai V; Matsuzaki K; Tanaka H; Miura S; Kim YS
Arch Pathol Lab Med; 2008 Jun; 132(6):958-64. PubMed ID: 18517279
[TBL] [Abstract][Full Text] [Related]
20. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.
Ogino S; Kawasaki T; Kirkner GJ; Ohnishi M; Fuchs CS
BMC Cancer; 2007 May; 7():72. PubMed ID: 17474983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
